Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 9, 2011, Pages

  Sieswerda, Elske ^a   van Dalen, Elvira C ^a   Postma, Aleida ^b   Cheuk, Daniel K L ^c   Caron, Huib N ^a   Kremer, Leontien C M ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CREATINE PHOSPHATE; ENALAPRIL; PLACEBO; ANTINEOPLASTIC ANTIBIOTIC;

ANXIETY; ASYMPTOMATIC DISEASE; CANCER PATIENT; CANCER SURVIVOR; CARDIOTOXICITY; CHILDHOOD CANCER; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); COUGHING; DEPRESSION; DIZZINESS; DRUG EFFECT; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEART PALPITATION; HEPATITIS C; HUMAN; HYPOTENSION; MORTALITY; MUSCULOSKELETAL PAIN; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT RISK; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THORAX PAIN; URTICARIA; ADULT; CHEMICALLY INDUCED DISORDER; CHILD; META ANALYSIS; SURVIVOR;

ADULT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CHILD; ENALAPRIL; HEART FAILURE; HUMANS; PHOSPHOCREATINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVORS;

EID: 80055082675     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008011.pub2     Document Type: Review

References (62)

1. Chen C, Zhou X-Z, Fan Y-M, Qin L-J, Guo H-X, Xue H-M, et al.Clinical analysis of Sodium phosphoceatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment 2008;15(19):1503-5, 510.
2. Greevy R, Lu B, Silber JH, Rosenbaum PR. Optimal multivariate matching before randomization. Biostatistics 2004;5(2):263-75.
3. Greevy R, Silber JH, Cnaan A, Rosenbaum PR. Randomization inference with imperfect compliance in the ACE-inhibitor after anthracycline randomized trial. Journal of the American Statistical Association 2004;99(465):7-15.
4. Silber JH. Challenges in conducting a pediatric longitudinal prevention study: lessons from the ACE-inhibitor after anthracycline trial. Progress in Pediatric Cardiology 2005;20:65-70.
5. Silber JH. The role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood & Cancer 2005;44:607-13.
6. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AHJ, Rychik J, et al.Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors. American Heart Journal 2001;142:577-85.
7. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, et al.Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology 2004;22(5):820-8.
8. Garcia JA, Simvoulidis LF, Salluh JI, Hansen MH, Feres GA, Holanda GS, et al.Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity. International Journal of Cardiology 2007;118:406-7.
9. Ginsberg JP, Cnaan A, Zhao H, Clark BJ, Paridon SM, Chin AJ, et al.Using health-related quality of life measures to predict cardiac function in survivors exposed to anthracyclines. Journal of Clinical Oncology 2004;22(15):3149-55.
10. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al.Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007;298(10):1171-9.
11. Shaddy RE, Curtin EL, Sower B, Tani LY, Burr J, LaSalle B, et al.The pediatric randomized carvedilol trial in children with heart failure: rationale and design. American Heart Journal 2002;144(3):389-9.
12. Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, et al.Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. Journal of Heart Lung Transplant 2005;24:2196-201.
13. Vatutin NT, Keting EV, Kalinkina NV, Dunaeva OA, Kardashevskaia LI. Effect of propranolol in silent myocardial ischemia induced by anthracyclines [Vliianie propranolola na bezbolevuiu ishemiiu miokarda, vyzvannuiu antratsiklinami]. Likars'ka sprava 2001, (1):106-9.
14. Mandric CG, Miron I, Dimitriu AG, Baghiu D, Dimitriu L, Miron OT. The utility of enalapril treatment in anthracyclines-induced cardiac injury in children with malignancies-preliminary study. Proceedings of the 40th Annual conference of International Society of Paediatric Oncology (SIOP), 2 - 6 Oct 2008, Berlin, Germany. 2008:Abstract L.030, print: 207-8.
15. Mandric CG, Miron I, Dimitriu AG, Dumitriu IL. Cardiac biomarkers in early detection of cardiotoxicity anthracycline-induced in children. Proceedings of the 41st Annual conference of International Society of Paediatric Oncology (SIOP), 5 - 9 Oct 2009, Sao Paulo, Brazil. 2009:Abstract PQ.020, Pediatric Blood & Cancer 2009;53:858.
16. Afterload Reduction Therapy for Late Anthracycline Cardiotoxicity: A Pediatric Oncology Group Cancer Control Study. http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT00003070.
17. Abdulla J, Pogue J, Abildstrom SZ, Kober L, Christensen E, Pfeffer MA, et al.Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction - a meta-analysis. European Journal of Heart Failure 2006;8(1):90-6.
18. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al.Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology 2010;55(3):213-20.
19. No authors listed. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353(9146):9-13.
20. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, version 3.0. Arcadia, CA. 2006. Available at: www.survivorshipguidelines.org.
21. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001;345(23):1667-75.
22. Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, et al.Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007;116(1):49-56.
23. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology 1999;33(4):916-23.
24. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002;287(7):883-9.
25. Ganame J, Claus P, Uyttebroeck A, Renard M, D'hooge J, Bijnens B, et al.Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. Journal of the American Society of Echocardiography 2007;20(12):1351-8.
26. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273(18):1450-6.
27. Glick H, Cook J, Kinosian B, Pitt B, Bourassa MG, Pouleur H, et al.Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. Journal of Cardiac Failure 1995;1(5):371-80.
28. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362(9386):772-6.
29. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
30. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996;347(8997):297-9.
31. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Annals of Oncology 2002;13(5):699-709.
32. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361(9372):1843-8.
33. Kay JD, Colan SD, Graham TP Jr. Congestive heart failure in pediatric patients. American Heart Journal 2001;142(5):923-8.
34. Kremer LC, Van Der Pal HJ, Offringa M, Van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology 2002;13(6):819-29.
35. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32(2):302-14.
36. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New England Journal of Medicine 1991;324(12):808-15.
37. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC, Shaikh SL, Mone SM, et al.Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. Journal of Clinical Oncology 2002;20(23):4517-22.
38. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al.Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 2005;23(12):2629-36.
39. Lipshultz SE, Vlach SA, Lipsitz SR, Sallan SE, Schwartz ML, Colan SD. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 2005;115:1613-22.
40. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology 2002;40(8):1414-21.
41. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362(9386):767-71.
42. Kremer LCM, Van Dalen EC, Moher D, Caron HN. Childhood Cancer Group. About the Cochrane Collaboration (Cochrane Review Groups CRGs) 2008, issue 4. www.thecochranelibrary.com.
43. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Edition. Boston, Mass: Little, Brown & Co, 1994.
44. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. New England Journal of Medicine 1996;334(21):1349-55.
45. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al.Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94(11):2793-9.
46. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
47. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008.
48. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, et al.Quality of life among 5, 025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology 1994;23(2):393-400.
49. Scottish Intercollegiate Guideline Network (SIGN). Long-term follow up care of survivors of childhood cancer. 2004. Guideline no. 76: available at: http://www.sign.ac.uk/pdf/sign76.pdf.
50. Skinner R, Wallace WH, Levitt G. Therapy based long term follow up: A practice statement (second edition). United Kingdom Children's Cancer Study Group, Late Effects Group. 2005. Available at: www.ukccsg.org.
51. No authors listed. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New England Journal of Medicine 1991;325(5):293-302.
52. No authors listed. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. New England Journal of Medicine 1992;327(10):685-91.
53. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003;97(8):1991-8.
54. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al.Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the Children's Cancer Study Group. Pediatrics 1992;89:942-9.
55. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Medical and Pediatric Oncology 1995;24(6):352-61.
56. Van Dalen EC, Van Der Pal HJ, Van Den Bos C, Caron HN, Kremer LC. Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence. Journal of Clinical Oncology 2003;21(17):3377-8.
57. Van Dalen EC, Van Der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. European Journal of Cancer 2006;42(18):3191-8.
58. Van Dalen EC, Van Den Brug M, Caron HN, Kremer LC. Anthracycline-induced cardiotoxicity: Comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. European Journal of Cancer 2006;42:3199-3205.
59. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. American Journal of Medicine 1977;62(2):200-8.
60. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al.Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342(8885):1441-6.
61. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108(8):977-82.
62. Wilson JMG, Jungner G. Principles and practice of screening for disease. WHO Chronicle 1968;22(11):473.